AU2002314325B8 - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents
Pyrrolopyrimidines as protein kinase inhibitors Download PDFInfo
- Publication number
- AU2002314325B8 AU2002314325B8 AU2002314325A AU2002314325A AU2002314325B8 AU 2002314325 B8 AU2002314325 B8 AU 2002314325B8 AU 2002314325 A AU2002314325 A AU 2002314325A AU 2002314325 A AU2002314325 A AU 2002314325A AU 2002314325 B8 AU2002314325 B8 AU 2002314325B8
- Authority
- AU
- Australia
- Prior art keywords
- group
- compound according
- alkyl
- compounds
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title description 2
- 239000003909 protein kinase inhibitor Substances 0.000 title description 2
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 178
- -1 y rx Chemical group 0.000 claims description 78
- 125000000217 alkyl group Chemical group 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 49
- 125000001072 heteroaryl group Chemical group 0.000 claims description 37
- 239000002253 acid Substances 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 25
- 125000001041 indolyl group Chemical group 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- 150000001204 N-oxides Chemical class 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 108090000461 Aurora Kinase A Proteins 0.000 claims description 9
- 102100032311 Aurora kinase A Human genes 0.000 claims description 9
- 108091000080 Phosphotransferase Proteins 0.000 claims description 9
- 102000001253 Protein Kinase Human genes 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 9
- 102000020233 phosphotransferase Human genes 0.000 claims description 9
- 108060006633 protein kinase Proteins 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 7
- 230000003197 catalytic effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 230000001668 ameliorated effect Effects 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000018937 joint inflammation Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims description 2
- UVPSSGJTBLNVRE-UHFFFAOYSA-N Moniliformin Natural products O=C1C(OC)=CC(=O)C=2C1=C1C(=O)C(OC)=CC(=O)C1=CC=2 UVPSSGJTBLNVRE-UHFFFAOYSA-N 0.000 claims description 2
- 206010047124 Vasculitis necrotising Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- KGPQKNJSZNXOPV-UHFFFAOYSA-N moniliformin Chemical compound OC1=CC(=O)C1=O KGPQKNJSZNXOPV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010048768 Dermatosis Diseases 0.000 claims 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 102000029301 Protein S Human genes 0.000 claims 1
- 108010066124 Protein S Proteins 0.000 claims 1
- 241001275899 Salta Species 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 53
- 239000000243 solution Substances 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 25
- 238000010992 reflux Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 235000019341 magnesium sulphate Nutrition 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 239000000377 silicon dioxide Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000005859 coupling reaction Methods 0.000 description 12
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 11
- 230000008878 coupling Effects 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 11
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 10
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000012458 free base Substances 0.000 description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000006978 adaptation Effects 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 6
- 102000000551 Syk Kinase Human genes 0.000 description 6
- 108010016672 Syk Kinase Proteins 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 6
- DWAQDRSOVMLGRQ-UHFFFAOYSA-N 5-methoxyindole Chemical compound COC1=CC=C2NC=CC2=C1 DWAQDRSOVMLGRQ-UHFFFAOYSA-N 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 108091008875 B cell receptors Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000005530 alkylenedioxy group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000003435 aroyl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 238000000105 evaporative light scattering detection Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- ZXUCBXRTRRIBSO-UHFFFAOYSA-L tetrabutylazanium;sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC ZXUCBXRTRRIBSO-UHFFFAOYSA-L 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CIOHGPFLKDLIQF-UHFFFAOYSA-N 3-borono-1-tert-butyl-5-methoxyindole-2-carboxylic acid Chemical compound COC1=CC=C2N(C(C)(C)C)C(C(O)=O)=C(B(O)O)C2=C1 CIOHGPFLKDLIQF-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 102100035634 B-cell linker protein Human genes 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000003302 alkenyloxy group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 3
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003791 organic solvent mixture Substances 0.000 description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- BTOJSYRZQZOMOK-UHFFFAOYSA-N 4-chloro-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(Cl)=C2C=C1 BTOJSYRZQZOMOK-UHFFFAOYSA-N 0.000 description 2
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical group N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 2
- 101710083670 B-cell linker protein Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- HVQUTNWOXNKNEK-UHFFFAOYSA-N [5-methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]boronic acid Chemical compound COC1=CC=C2N(C(=O)OC(C)(C)C)C=C(B(O)O)C2=C1 HVQUTNWOXNKNEK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000005239 aroylamino group Chemical group 0.000 description 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000024321 chromosome segregation Effects 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 108010042617 dinitrophenyl-human serum albumin conjugate Proteins 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 150000003893 lactate salts Chemical class 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- PTTHBZMGHRDZCV-UHFFFAOYSA-N 1h-indol-3-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CNC2=C1 PTTHBZMGHRDZCV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IKCZUPRWPVLSLF-UHFFFAOYSA-N 2-methoxy-1h-indole Chemical compound C1=CC=C2NC(OC)=CC2=C1 IKCZUPRWPVLSLF-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- QYBXZYYECZFQRX-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)benzoic acid Chemical class C1=CC(C(=O)O)=CC=C1CN1CCOCC1 QYBXZYYECZFQRX-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical class O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- DRNWHEZFQFFNEW-UHFFFAOYSA-N 4-chloro-6-iodo-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(Cl)=C2C=C1I DRNWHEZFQFFNEW-UHFFFAOYSA-N 0.000 description 1
- RTTFJIAJWSWATI-UHFFFAOYSA-N 4-methoxy-6-(5-methoxy-1h-indol-3-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1OC RTTFJIAJWSWATI-UHFFFAOYSA-N 0.000 description 1
- NZIMCWNHZCDFQF-UHFFFAOYSA-N 4-methoxy-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC=2C(OC)=NC=NC=2N1S(=O)(=O)C1=CC=C(C)C=C1 NZIMCWNHZCDFQF-UHFFFAOYSA-N 0.000 description 1
- QGJOWBMQGBHKRM-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=NC=NC2=C1C=CN2 QGJOWBMQGBHKRM-UHFFFAOYSA-N 0.000 description 1
- OIXXVIAONIAEED-UHFFFAOYSA-N 6-(5-methoxy-1h-indol-3-yl)-4-[5-methoxy-1-(4-methylphenyl)sulfonylindol-3-yl]-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(C=3C4=CC(OC)=CC=C4N(C=3)S(=O)(=O)C=3C=CC(C)=CC=3)N=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 OIXXVIAONIAEED-UHFFFAOYSA-N 0.000 description 1
- HRXLWKRUWPTJBF-UHFFFAOYSA-N 6-iodo-4-methoxy-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound IC1=CC=2C(OC)=NC=NC=2N1S(=O)(=O)C1=CC=C(C)C=C1 HRXLWKRUWPTJBF-UHFFFAOYSA-N 0.000 description 1
- SPKCKEXXOLYDGR-UHFFFAOYSA-N 6-iodo-7-(4-methylphenyl)sulfonyl-4-pyridin-3-ylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(C=3C=NC=CC=3)=C2C=C1I SPKCKEXXOLYDGR-UHFFFAOYSA-N 0.000 description 1
- XVSYSFCRJYLVRN-UHFFFAOYSA-N 7-(4-methylphenyl)sulfonyl-4-pyridin-3-ylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(C=3C=NC=CC=3)=C2C=C1 XVSYSFCRJYLVRN-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 102000003989 Aurora kinases Human genes 0.000 description 1
- 108090000433 Aurora kinases Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 101100388509 Caenorhabditis elegans che-3 gene Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 1
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- VNEMVKOXLBIWTB-UHFFFAOYSA-N aminomethyl benzoate Chemical class NCOC(=O)C1=CC=CC=C1 VNEMVKOXLBIWTB-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000006360 carbonyl amino methylene group Chemical group [H]N(C([*:1])=O)C([H])([H])[*:2] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- OJKBCQOJVMAHDX-UHFFFAOYSA-N diethyl(pyridin-3-yl)borane Chemical compound CCB(CC)C1=CC=CN=C1 OJKBCQOJVMAHDX-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000017793 embryonic organ development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- LPWAKYISHIZIPO-UHFFFAOYSA-N morpholin-4-ylmethyl benzoate Chemical class C=1C=CC=CC=1C(=O)OCN1CCOCC1 LPWAKYISHIZIPO-UHFFFAOYSA-N 0.000 description 1
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200087814 rs56384680 Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- DCTZDUWRIAYEIF-UHFFFAOYSA-N tert-butyl 3-bromo-5-methoxyindole-1-carboxylate Chemical compound COC1=CC=C2N(C(=O)OC(C)(C)C)C=C(Br)C2=C1 DCTZDUWRIAYEIF-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LGQXXHMEBUOXRP-UHFFFAOYSA-N tributyl borate Chemical compound CCCCOB(OCCCC)OCCCC LGQXXHMEBUOXRP-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
WO 03/000695 PCT/GB02/02835 1- PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS This invention is directed to substituted pyrrolopyrimidines, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the protein kinases.
Protein kinases participate in the signalling events which control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in the environment. In general, these kinases fall into several groups; those which preferentially phosphorylate serine and/or threonine residues and those which preferentially phosphorylate tyrosine residues [S.K.Hanks and T.Hunter, FASEB. 1995, 9, pages 576-596]. The serine/threonine kinases include for example, protein kinase C isoforms [A.C.Newton, J. Biol. Chem., 1995, 270, pages 28495-28498] and a group of cyclin-dependent kinases such as cdc2 [J.Pines, Trends in Biochemical Sciences, 1995, 18, pages 195-197]. The tyrosine kinases include membrane-spanning growth factor receptors such as the epidermal growth factor receptor [S.Iwashita and M.Kobayashi, Cellular Signalling, 1992, 4, pages 123-132], and cytosolic non-receptor kinases such as p56tck, p59fYn, ZAP-70 and csk kinases [C.Chan et. al., Ann. Rev. Immunol., 1994,12, pages 555-592].
Inappropriately high protein kinase activity has been implicated in many diseases resulting from abnormal cellular function. This might arise either directly or indirectly, for example by failure of the proper control mechanisms for the kinase, related for example to mutation, over-expression or inappropriate activation of the enzyme; or by over- or underproduction of cytokines or growth factors also participating in the transduction of signals upstream or downstream of the kinase. In all of these instances, selective inhibition of the action of the kinase might be expected to have a beneficial effect.
Syk is a 72-kDa cytoplasmic protein tyrosine kinase that is expressed in a variety ofhematopoietic cells and is an essential element in several cascades that couple antigen receptors to cellular responses.
Thus, Syk plays a pivotal role in signalling of the high affinity IgE receptor, FcsRI, in mast cells and in receptor antigen signalling in T and B lymphocytes. The signal transduction pathways present in mast, T and B cells have common features. The ligand binding domain of the receptor lacks intrinsic tyrosine kinase activity. However, they interact with transducing subunits that contain immunoreceptor tyrosine based activation motifs (ITAMs) [M.Reth, Nature, 1989, 338, pages 383- 384]. These motifs are present in both the 3 and y subunits of the FceR1, in the a-subunit the of T cell receptor (TCR) and in the IgGa and IgG P subunits of the B cell receptor (BCR). [N.S.van Oers and A.Weiss, Seminars in Immunology, 1995, 7, pages 227-236] Upon binding of antigen and WO 03/000695 PCT/GB02/02835 -2multimerization, the ITAM residues are phosphorylated by protein tyrosine kinases of the Src family.
Syk belongs to a unique class of tyrosine kinases that have two tandem Src homology 2 (SH2) domains and a C terminal catalytic domain. These SH2 domains bind with high affinity to ITAMs and this SH2 -mediated association of Syk with an activated receptor stimulates Syk kinase activity and localises Syk to the plasma membrane.
In Syk deficient mice, mast cell degranulation is inhibited, suggesting that this is an important target for the development of mast cell stabilising agents [P.S.Costello, Oncogene, 1996, 13, pages 2595- 2605]. Similar studies have demonstrated a critical role for Syk in BCR and TCR signalling [A.M.Cheng, Nature, 1995, 378, pages 303-306, (1995) and D.H.Chu et al., Immunological Reviews, 1998, 165, pages 167-180]. Syk also appears to be involved in eosinophil survival in response to and GM-CSF [S.Yousefi et al., J. Exp. Med., 1996, 183, pages 1407-1414]. Despite the key role of Syk in mast cell, BCR and T cell signalling, little is known about the mechanism by which Syk transmits downstream effectors. Two adaptor proteins, BLNK (B cell Linker protein, SLP-65) and SLP-76 have been shown to be substrates of Syk in B cells and mast cells respectively and have been postulated to interface Syk with downstream effectors [M.Ishiai et al., Immunity, 1999, 10, pages 117- 125 and L.R.Hendricks-Taylor et al., J.Biol. Chem, 1997, 272, pages 1363-1367]. In addition Syk appears to play an important role in the CD40 signalling pathway, which plays an important role in B cell proliferation [M.Faris et al., J.Exp. Med., 1994, 179, pages 1923-193 Syk is further involved in the activation of platelets stimulated via the low-affinity IgG receptor (Fc gamma-RIIA) or stimulated by collagen [F.Yanaga et al., Biochem. 1995, 311, (Pt. 2) pages 471- 478].
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase involved in integrin-mediated signal transduction pathways. FAK colocalizes with integrins in focal contact sites and FAK activation and its tyrosine phosphorylation have been shown in many cell types to be dependent on integrins binding to their extracellular ligands. Results from several studies support the hypothesis that FAK inhibitors could be useful in cancer treatment. For example, FAK-deficient cells migrate poorly in response to chemotactic signals and overexpression of C-terminal domain of FAK blocks cell spreading as well as chemotactic migration (Sieg et al, J. Cell Science,1999, 112, 2677-2691; Richardson A. and Parsons Cell, 1997, 97, 221-231) in addition, tumor cells treated with FAK antisense oligonucleotides lost their attachment and underwent apoptosis (Xu et al, Cell Growth Differ. 1996, 4, 413-418). FAK has been reported to be overexpressed in prostate, breast, thyroid, colon and lung cancers. The level of expression of FAK is directly correlated with tumors demonstrating the most aggressive phenotype.
WO 03/000695 PCT/GB02/02835 -3- Angiogenesis or the formation of new blood vessels by sprouting from the preexisting vasculature is of central importance for embryonic development and organogenesis. Abnormal enhanced neovascularization is observed in rheumatoid arthritis, diabetic retinopathy and during tumor development (Folkman, Nat. Med., 1995, 1, 27-31.). Angiogenesis is a complex multistage process which includes activation, migration, proliferation and survival of endothelial cells. Extensive studies in the field of tumor angiogenesis in the past two decades have identified a number of therapeutic targets including kinases, proteases and integrins resulting in the discovery of many new antiangiogenic agents, including KDR inhibitors some of which are currently under clinical evaluation (Jekunen, et al Cancer Treatment Rev. 1997, 23, 263-286.). Angiogenesis inhibitors may be used in frontline, adjuvant and even preventive settings for the emergence or regrowth of malignancies.
Several proteins involved in chromosome segregation and spindle assembly have been identified in yeast and drosophila. Disruption of these proteins results in chromosome missegregation and monopolar or disrupted spindles. Among these kinases are the Ipll and aurora kinases from S.cerevisiae and drosophila respectively, which are required for centrosome separation and chromosome segregation. One human homologue of yeast Ipll was recently cloned and characterized by different laboratories. This kinase termed Aurora2, STK15 or BTAK belongs to the serine/threonine kinase family. Bischoff et al showed that Aurora2 is oncogenic and is amplified in human colorectal cancers (EMBO J, 1998, 17, 3052-3065). It has also been exemplified in cancers involving epithelial tumors such as breast cancer.
10-Dec-2008 17:01 Wattermark +61298887600 7/38 004 O This invention concerns substituted pyrrolopyrliniddines of formula which have the ability to inhibit one or more protei n ldna~sesq, more particularly, FAK, KDR, Syk inase or- Aurora2, especially Syk kinase.
4 en7 7 Iq 2 wherein
R.
1 represents hydrogen, -C(=O)-NY 1
Y
2 5 -S0 2
-NY
1
Y
2 -S0 2 -11 7
-C(-O)R
7 or
R.
1 represents alkenyl, alkenyloxy, alkyl, alicyyl, aryl, heteroaryl, heterocycloalkyl, cycloalky or cycloallcylalkyl, each optionally substituted by one or more groups selected from. aryl, cyclonilcl, cyano, halo, heteroaryl, beterocycloalcy, -CHIO or a 57, 6- or 7-meinbered cyclic acetal derivative of such -CHO, 1
Y
2 -CtO)-OR5, -Ny 1
Y
2
-N(R
6 )-C&Q0)-R 7
-N(R
6
)-CQ=Q)-NY
3 Y4, -N(R 6 )-S0 2
-R
7
'-N(R
6 )-S0) 2
-NY
3 y 4
-OR
7 7 hydroxy, alkoxy and carboxy;
R.
2 represents one or more groups selected from hydrogen, acyl, alkylenedioxy, alkenyl, alkenayloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocyclonilcyl, itro, R.
4 -C&Q0)-NY'Y 2 -CQ=O)-0R 5 -NY 1
Y
2
-N(R
6 7
-N(R
6 3 y 4
-N(R
6 7
-N(.R
6 )-S0 2
-R
7
-N(R
6 )-S0-NY 3
Y
4 -S0 2 -Y Y 2 and -Z-R 4
R
3 represents H, cyano, halo, hydroxy, rntro, R.
4
NY
1
Y
2
-ZR
4 -C(=O)-0R 5 7 -C(=O)-NYlY 2
-N(R
8 4
-N(R
8 1
Y
2
-N(R
8 5 -50 2 -Ny 3
Y
4 or -NCR 8 )-S0 2
-R
7 or
R.
3 represents aryl, heteroaryl, alkenyl or alkynyl, each optionally substituted by one or more groups selected. from aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, itro, NY] Y 2 -C(=O)-0R 5
-NY
1
Y
2
-N(R
6 7
-N(R
6 3
Y
4
-N(R
6
-N(R
6 )-S0 2
-R
7
-N(R,
6 )-S0 2
-NY
3
Y
4 -50 2
-NY
1
Y
2 and -ZR 4 COMS ID No: ARCS-216599 Received by iP Australia: Time 17:29 Date 2008-12-10 .0-Dec-2008 17:02 'Watermark +61298887600 8/38 005 0 ~iZ represents alkcyl, cycloalicyl or cycloalkylalkyl each optionally substituted by one or more o groups selected from axyl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, hydroxy, -CEO 0 or a 6- or 7-mrentered cyclic acetal derivative ofT such -CHO, y 2 -C®O0)-0R 5 2 Nyly 2
-N(R
6
)-CQO)-R
7
-N(R
6 3 74, -N(R 6 )-S0 2 -R7, -N(R 6 )-S0 2 -WY3y4,-
SOR
7 and -CQ=-O)-R 7 [[where R 4 is optionally interspersed with a group selected from 0, S(O)n, tfl and NR 6 fl; en HR 5 represents hydrogen, alkyl, alkenyl, aryl, arylailcyl, heteroaryl or heteroarylalkyl; R6represents hydrogen or lower alkyl; R7represents alkyl, aryl, arylalkyl, cycloalkyl, cycloallcylalkyl, heteroaryl, heteroarylalkyl, 0 10 heterocycloalkyl. or heterocycloalkylalkyl; R8represents hydrogen or lower ailkyl;
Y
1 and Y 2 are independently hydrogen, alcenyl, aryl, cyoloalkyl, heterosryl or ailkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, hydroxy, -CQwO)-NY 3
Y
4 -C&=O)-0R 5 -Ny 3 y'! 4
-N(R.
6 7 -N(R%)-C(oO)-NY 3
Y
4
-N(R
6 )-80 2 -Ny 3 y 4 and -OR 7 or the group -NY 1
Y
2 may form a cyclic amine; y 3 and y 4 are independently hydrogen, ailcenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY 3
Y
4 may form a cyclic amine; Z represents 0 Or ()n n is zero or an integer I or 2; or an N-oxide, an acid bioisostere selected from the group consisting of:
CT
2 OI'I, -C(;mO)-CE 2 ST, -C(=0O)-NH-CN, snubf, phosphono, allcylsulfonlyloarbarnoyl, tetrazolyl, arylsulfontylcarbamoy], beteroarylsulfonylearbamnoyl, N-methoxycarbainoyl, 3-hydroxy-3cyclobutene- 1,2-diane, 3,5-dioxo-l ,2,4-oxadiazolidinyl, 3-hydroxyisoxazolyl and 3-hydroxy-l-methylpyrazolyl; a pharmaceutically acceptable salt of such compound; or an Noxide, or acid bioisostere selected from the group consisting of-~ -C(=O)-NBOH, -C(0)-C1 2 01,
-CQ=O)-CH
2 S-J, sulfa, phosphono, alkylsulfonylearbamoyl, tetrazolyl, arylsulfonylcarbainoyl, hecteroarylsulfonylcarbamoyl, N-mnethoxycarbamoyl, 3-hydroxy-3oyclohutene-l ,2-dione, 3,5-dioxo-l ,2,4-oxadiazolidinyl, 3-hydroxyisoxazolyl and 3-hydoxy-l-methylpyrazoly; of such salt; together with one or miore pharmacutically acceptable carriers or excipients.
COMS ID No: ARCS-216599 Received by IP Australia: Time (I-tm) 17:29 Date 2008-12-10 10-Dec-2008 17:03 Watermark +61298887600 9/38 00 0 O In the present specification, the term "compounds of the invention", and equivalent expressions, o are meant to embrace compounds of general formula as hereinbefore described, which Sexpression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g.
Shydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes l T indicated in the text, but these instances are purely illustrative and it is not intended to exclude M other instances when the context so permits.
M 10 As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings:- "Patient" includes both human and other mammals.
4.
V
COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10 WO 03/000695 PCT/GB02/02835 -6- "Acid bioisostere" means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1 9 86, 2 1,p 2 8 3 "Bioisosterism In Drug Design"; Yun, Hwahak Sekye, 1993, 33, pages 576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue Tongbao, 1995, pages 34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design"; Graham, Theochem, 1995, 343, pages 105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid bioisosteres include: -C(=O)-NHOH, -C(=O)-CH20H, -C(=O)-CH 2 SH, sulfo, phosphono, alkylsulfonylcarbamoyl, tetrazolyl, arylsulfonylcarbamoyl, heteroarylsulfonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-l,2,4-oxadiazolidinyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and 3-hydoxy-l-methylpyrazolyl.
"Acyl" means an H-CO- or alkyl-CO- group in which the alkyl group is as described herein.
"Acylamino" is an acyl-NH- group wherein acyl is as defined herein.
"Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms 2 to 4 carbon atoms) in the chain. "Branched," as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain, which may be straight or branched. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.
"Alkenyloxy" is an alkenyl-O- group wherein alkenyl is as defined above. Exemplary alkenyloxy groups include allyloxy.
"Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include difluoromethoxy, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.
"Alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein.
Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.
WO 03/000695 PCT/GB02/02835 -7- "Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched chain having about 1 to about 15 carbon atoms in the chain, optionally substituted by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. "Lower alkyl" as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be a straight or branched chain having 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, heptyl, octyl, nonyl, decyl and dodecyl.
Exemplary alkyl groups substituted by one or more halogen atoms include trifluoromethyl.
"Alkylene" means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.
"Alkylenedioxy" means an -O-alkylene-O- group in which alkylene is as defined above. Exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.
"Alkylsulfinyl" means an alkyl-SO- group in which the alkyl group is as previously described.
Preferred alkylsulfinyl groups are those in which the alkyl group is Cl-4alkyl.
"Alkylsulfonyl" means an alkyl-S0 2 group in which the alkyl group is as previously described.
Preferred alkylsulfonyl groups are those in which the alkyl group is Cl-4alkyl.
"Alkylsulfonylcarbamoyl" means an alkyl-SO2-NH-C(=O)- group in which the alkyl group is as previously described. Preferred alkylsulfonylcarbamoyl groups are those in which the alkyl group is
C
1 .4alkyl.
"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, isopropylthio and heptylthio.
"Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which group may be a straight or branched chain having about 2 to about 15 carbon atoms in the chain.
Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms 2 to 4 carbon atoms) in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.
WO 03/000695 PCT/GB02/02835 8- "Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.
"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.
"Aryl" as a group or part of a group denotes: an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Except where otherwise defined, aryl groups may be substituted with one or more aryl group substituents, which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, -NY 3
Y
4
-CONY
3
Y
4
-SO
2
NY
3
Y
4
-NY
3 -C(=O)alkyl,
-NY
3
SO
2 alkyl or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or -NY 3
Y
4 "Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a Cl -4alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.
"Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl groups is as previously described.
Exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which the arylalkyl groups is as previously described. An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.
"Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described.
An exemplary arylalkylthio group is benzylthio.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Exemplary aryloxy groups include phenoxy and naphthoxy, each optionally substituted.
"Aryloxycarbonyl" means an aryl-O-C(=0)- group in which the aryl group is as previously described.
Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
WO 03/000695 PCT/GB02/02835 -9- "Arylsulfinyl" means an aryl-SO- group in which the aryl group is as previously described.
"Arylsulfonyl" means an aryl-SO 2 group in which the aryl group is as previously described.
"Arylsulfonylcarbamoyl" means an aryl-S0 2 group in which the aryl group is as previously described.
"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Exemplary arylthio groups include phenylthio and naphthylthio.
"Azaheteroaryl" means an aromatic carbocyclic moiety of about 5 to about 10 ring members in which one of the ring members is nitrogen and the other ring members are selected from carbon, oxygen, sulfur, and nitrogen. Examples of azaheteroaryl groups include benzimidazolyl, imidazolyl, indazolinyl, indolyl, isoquinolinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, quinazolinyl and tetrahydroindolizinyl.
"Cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system wherein one of the ring carbon atoms is replaced by nitrogen and which may also contain a further heteroatom-containing group selected from O, S, SO2, or NY 5 (where Y 5 is hydrogen, alkyl, aryl, arylalkyl, 7 -C(=0)-OR 7 or -SO 2
R
7 and (ii) may be fused to additional aryl phenyl), heteroaryl (e.g.
pyridyl), heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system. Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline, pyrindoline, tetrahydroquinoline and the like groups.
"Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl and cycloheptenyl.
"Cycloalkyl" means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms, optionally substituted by oxo. Exemplary monocyclic cycloalkyl rings include C 3 _gcycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.
WO 03/000695 PCT/GB02/02835 "Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro and chloro.
"Heteroaroyl" means a heteroaryl-C(=O)- group in which the heteroaryl group is as described herein.
Exemplary heteroaryl groups include pyridylcarbonyl.
"Heteroaroylamino" means a heteroaroyl-NH- group in which the heteroaryl moiety is as previously described.
"Heteroaryl" as a group or part of a group denotes: an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur (examples of such groups include benzimidazolyl, benzthiazolyl, furyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above except where otherwise defined); (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure (examples of such groups include pyrindanyl groups, optionally substituted by one or more "aryl group substituents" as defined above, except where otherwise defined). Optional substituents include one or more "aryl group substituents" as defined above, except where otherwise defined.
"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C -4alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
Heteroarylalkyloxy" means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.
"Heteroaryloxy" means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.
WO 03/000695 PCT/GB02/02835 11- "Heteroarylsulfonylcarbamoyl" means a heteroaryl-S0 2 group in which the heteroaryl group is as previously described.
"Heterocycloalkyl" means: a cycloalkyl group of about 3 to 7 ring members which contains one or more heteroatoms or heteroatom-containing groups selected from O, S and NY 5 and mat be optionally substituted by oxo; (ii) a partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl) ring, each optionally substituted by one or more "aryl group substituents," and a heterocycloalkyl group are fused together to form a cyclic structure. (Examples of such groups include chromanyl, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).
"Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.
"Prodrug" means a compound which is convertible in vivo by metabolic means by hydrolysis) to a compound of formula including N-oxides thereof. For example an ester of a compound of formula containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule.
Alternatively, an ester of a compound of formula containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.
Suitable esters of compounds of formula containing a hydroxy group are, for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-P-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.
Suitable esters of compounds of formula containing a carboxy group are, for example, those described by F.J.Leinweber, Drug Metab. Res., 1987, 18, page 379.
Suitable esters of compounds of formula containing both a carboxy group and a hydroxy group within the moiety -L 1 -Y include lactones formed by loss of water between said carboxy and hydroxy groups. Examples of such lactones include caprolactones and butyrolactones.
An especially useful class of esters of compounds of formula containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32 page 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted WO 03/000695 PCT/GB02/02835 -12by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin- 1-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin- -yl)benzoates.
Where the compound of the invention contains a carboxy group, or a sufficiently acidic bioisostere, base addition salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.
Some of the compounds of the present invention are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.
Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobromides, sulfates, phosphates, nitrates, sulfamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-beta-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, WO 03/000695 PCT/GB02/02835 -13methane-sulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.
As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.
With reference to formula above, the following are particular and preferred groupings: R1 may particularly represent: hydrogen (ii) C 1
I
4 alkyl -CH 3 or -CH 2
CH
3 (iii) Cl_ 4 alkyl substituted by halo -CH 2
CF
3 (iv) C 1 4 alkyl substituted by hydroxy -CH 2 OH, -CH 2 CH2OH or -CH 2
CH
2
CH
2
OH];
C1_4alkyl substituted by-N(R 6 7
-CHCH
2
CH
2 NHC CH, (vi) CI-4alkyl substituted by -C(=O)-NY1y 2 -CH-C -N or H C-CH 21 1 2 (vii) cycloalkylalkyl substituted by hydroxy -C-CH
CH
2
OH
Compounds of formula in which R 1 represents hydrogen, -CH 3
-CH
2
CH
3
-CH
2
CF
3 or -CH2-C -N O are especially preferred. R 1 more especially represents hydrogen.
R2 may particularly represent:
N__NH
carboxy or an acid bioisostere
-N
(ii) hydroxy; (iii) alkyl substituted by carboxy -CH 2
CH
2 CO H WO 03/000695 PCT/GB02/02835 14- N H 3 (iv) heteroaryl \or pyridyl];
-OR
4 in which R 4 is alkyl -OCHR 3 (vi) -OR 4 in which R 4 is alkyl or cycloalkylalkyl substituted by one or more hydroxy groups e~g. -OCH 2 CH 2 OR, -OCH 2 CH 2 CH 2 OR, -OCH CHOH, H 2
C-CR
I 1 2 -OCH CH (OH) CH 3 5-OC-CR 2 or -OCH 2 CH (OH) CH 2
ORH];
(vii) -OR 4 in which R 4 is alkyl substituted by one or more alkoxy groups [e.g.
-OCH (CH 3
CH
2
OCH
3 ]1; (viii) -OR 4 in which R 4 is alkyl or cycloalkyl substituted by one or more carboxy groups [e.g.
H C-CH 2 to -OCH 2 CO 2 H, -OCR (CE 3
CO
2 H or -0--C-CR 2
COCONEH
HH C-CR CONHCH2 -C(0O)-R in which R is alkyl -c -cH]; (xi) -C(=O)-Nyly 2 -CONH 2
-CONHCH
3 ,-CONHCH (CH 2 OH) 2' -CONHCH 2
CH
2 0H, -CONHC (CHE 3 2
CH
2 OR, -CNHCH 2
CH
2
OCH
3
N
-CONCH CH CONH 2 -CONHCH C(CH 3 2 0H or -CONE ]or 2 2 2 3) .N_,NH (xii) -N(R 6 7 -NEC CHR 3 1.
WO 03/000695 PCT/GB02/02835 Compounds of formula in which R 2 represents -OCH 3 or -CONHC (CH 3 2
CH
2 OR are especially preferred. R 2 more especially represents -OCrr 3 R3may particularly represent: hydrogen; (ii) cyano; (iii) optionally substituted aryl phenyl); (iv) optionally substituted heteroaryl optionally substituted pyridyl or optionally MeO substituted indolyl, especially or/ or
N~
-N
H
alkyl methyl or ethyl); (vi) alkyl substituted by one or more halogen atoms trifluoromethyl); (vii) alkyl substituted by -C&=O)-NY 1 Iy 2 especially -CH 2
-CH
2
-C(=O)NHCH
3 (viii) alkyl substituted by -OR 7
-CH
2 -CH2-OCH 3 (ix) -ZR 4 especially -OCH 3
-OCH
2
CH
3
-OCF
2 H or -OCH 2
-CH
2
-OCH
3 -C(z=O)-OR 5 especially -C(0)-OH; (xi) 1 Iy 2 especially -C('=O)NHCH 3 or -C(0)-NH-C(CH 3 2
-CH
2 OH; and (xii) -NY 1 y 2 especially -N 0.
Compounds of formula in which R 3 represents hydrogen, cyano, pyridyl, trifluoromethyl. -CH 2
CH
2
-C(=O)NHCH
3
-OCF
2 H, -C(0)-NH-C(CH 3 2
-CH
2 OH or -N 0 are especially preferred. R 3 more especially represents -OCH 3 is preferably attached to position 5 of the indole ring.
WO 03/000695 PCT/GB02/02835 -16-
R
3
N
The group is preferably attached to the 3 position of the indole ring
N
H
It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.
Particular preferred compounds of the invention are:- 0J Me MeO 0 Me
CF
3 N 0 H 0
CH
3 (II) (III) OMe CONHMe MeO N H a. 0 (IV) (V) WO 03/000695 WO 03/00695PCT/GB02/02835 17- (VI) (VII) Meo 0 NH
NK
H
OIX)
(VIII)
(XI) (XII)
(XIII)
(XJY)
meo Meo (CH,)0 o
NH
H
(XVI)
Meo N N
H
(XVII) (XV) WO 03/000695 WO 03/00695PCT/GB02/02835 Meo Nb
H
(XVIII) (XIX) (XX) (XXI) (XXII) (XXIII) CH 2OH (XXIV) (XXV) (XXVI) (XX VII) and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.
Especially preferred compounds of the invention are:- WO 03/000695 PCT/GB02/02835 -19- Meo OMe N H H
(XII)
4-methoxy-6-(5-methoxy-1H-indol-3-yl)-7H-pyrrolo[2,3-d]pyrimidine; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates hydrates) of such compounds and their N-oxides and prodrugs.
The compounds of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, compounds of the invention and compositions containing compounds of the invention for use in therapy.
Compounds within the scope of the present invention block kinase catalytic activity according to tests described in the literature and in vitro procedures described hereinafter, and which tests results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further embodiment, the present invention provides compounds of the invention and compositions containing compounds of the invention for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of protein kinase Syk, FAK, KDR or Aurora2) inhibitors, in particular a Syk kinase inhibitor. For example, compounds of the present invention are useful in the treatment of inflammatory diseases, for example asthma: inflammatory dermatoses psoriasis, dematitis herpetiformis, eczema, necrotizing and cutaneous vasculitis, bullous disease); allergic rhinitis and allergic conjunctivitis; joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. The compounds are also useful in the treatment of Chronic Obstructive Pulmonary Disease (COPD), acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, collitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, multiple sclerosis, restenosis, myocarditis, B cell lymphomas, systemic lupus erythematosus, graft v host disease and other transplant associated rejection events, cancers and tumours (such as colorectal, prostate, breast, thyroid, colon and lung cancers) and inflammatory bowel disease. Additionally, the compounds are useful as tumor anti-angiogenic agents.
A special embodiment of the therapeutic methods of the present invention is the treating of asthma.
WO 03/000695 PCT/GB02/02835 Another special embodiment of the therapeutic methods of the present invention is the treating of psoriasis.
Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.
Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.
Another special embodiment of the therapeutic methods of the present invention is the treating of cancers and tumours.
According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of a protein kinase Syk, FAK, KDR or Aurora2) inhibitor for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of a compound of the invention or a composition containing a compound of the invention. "Effective amount" is meant to describe an amount of compound of the present invention effective in inhibiting the catalytic activity a protein kinase, such as Syk, FAK, KDR or Aurora2, and thus producing the desired therapeutic effect.
References herein to treatment should be understood to include prophylactic therapy as well as treatment of established conditions.
The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of the invention in association with a pharmaceutically acceptable carrier or excipient.
Compounds of the invention may be administered by any suitable means. In practice, compounds of the present invention may be administered parenterally, topically, rectally, orally or by inhalation, especially by the oral route.
Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable WO 03/000695 PCT/GB02/02835 -21solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavourings, colourings, or stabilisers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets.
To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols.
When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.
For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilised by heating, irradiation or microfiltration.
For topical administration, gels (water or alcohol based), creams or ointments containing compounds of the invention may be used. Compounds of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.
For administration by inhalation compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.
Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.
WO 03/000695 PCT/GB02/02835 -22- The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained.
Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient.
In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.
The compounds according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.
Compounds of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R.C.Larock in Comprehensive Organic Transformations, VCH publishers, 1989.
In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P.G.M.Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.
Compounds of formula wherein R 1
R
2 and R 3 are as hereinbefore defined, are prepared by reaction of compounds of formula (XXVIII):- WO 03/000695 PCT/GB02/02835 -23-
R
3
N^N
H
(XXVIII)
wherein R 3 is as hereinbefore defined and X 1 is a halogen, preferably iodine, atom or a triflate group, with compounds of formula (XXIX):- (HO) 2B 7 2
N
(XXIX)
wherein R 1 and R 2 are as defined hereinbefore. The coupling reaction may conveniently be carried out, for example, in the presence of a complex metal catalyst such as tetrakis(triphenylphosphine)palladium(0) and sodium bicarbonate, in aqueous dimethylformamide at a temperature up to reflux temperature. This reaction is conveniently carried out with the pyrrole NH in compound (XXVIII) protected with for example a tosyl group and the indole NH in compound (XXIX) protected with, for example, a tert-butyloxycarbonyl group.
Compounds of formula wherein R 2 and R 3 are as hereinbefore defined and R 1 is optionally substituted alkyl are prepared by reaction of the corresponding compounds of formula wherein R 2 and R 3 are as hereinbefore defined and R 1 is hydrogen with the appropriate alkyl halide R 2
-X
2 in which R 2 is optionally substituted alkyl and X 2 is halo. This reaction is particularly suitable for the preparation of compounds of formula wherein R1 is morpholinoacetyl.
Compounds of the invention may also be prepared by interconversion of other compounds of the invention.
Thus, for example, compounds of formula containing a carboxy group may be prepared by hydrolysis of the corresponding esters. The hydrolysis may conveniently be carried out by alkaline WO 03/000695 PCT/GB02/02835 -24hydrolysis using a base, such as an alkali metal hydroxide, e.g. lithium hydroxide, or an alkali metal carbonate, e.g. potassium carbonate, in the presence of an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol, at a temperature from about ambient to about reflux. The hydrolysis of the esters may also be carried out by acid hydrolysis using an inorganic acid, such as hydrochloric acid, in the presence of an aqueous/inert organic solvent mixture, using organic solvents such as dioxan or tetrahydrofuran, at a temperature from about 50 0 C to about 80 0
C.
As another example compounds of formula containing a carboxy group may be prepared by acid catalysed removal of the tert-butyl group of the corresponding tert-butyl esters using standard reaction conditions, for example reaction with trifluoroacetic acid at a temperature at about room temperature.
As another example compounds of formula containing a carboxy group may be prepared by hydrogenation of the corresponding benzyl esters. The reaction may be carried out in the presence of ammonium formate and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol and at a temperature at about reflux temperature. The reaction may alternatively be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.
As another example of the interconversion process, compounds of formula containing a
-C(=O)-NY
1y 2 group may be prepared by coupling compounds of formula containing a carboxy group with an amine of formula HNY 1
Y
2 to give an amide bond using standard peptide coupling procedures, for example coupling in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate and triethylamine (or diisopropylethylamine) in tetrahydrofuran (or dimethylformamide) at room temperature. This procedure is particularly useful for the preparation of(i) compounds of formula wherein R 3 represents -C(=O)-NY 1
Y
2 or (ii) compounds of formula wherein R 2 represents -C(=O)-NY 1 y 2 The coupling may also be brought about by reaction of compounds of formula containing a carboxy group with N- ((dimethylamino)( 1 H-1,2,3-triazaolo[4,5-b]pyridin-1 -yl)methylene}-N-methylmethanaminium hexafluorophosphate N-oxide in the presence of a suitable base, such as diisopropylethylamine, in an inert solvent, such as dimethylformamide, and at a temperature at about room temperature, followed by reaction with an amine of formula HNY Y 2 (ammonium chloride can be used for the preparation of compounds of formula containing a -C(=0)-NH 2 group). The coupling may also be brought about by reaction of compounds of formula containing a carboxy group with 2-(1H-benzotriazole-1- WO 03/000695 PCT/GB02/02835 yl)1,1,3,3-tetramethyluronium hexafluorophosphate, in dry dimethylformamide, followed by reaction with an amine of formula HNY 1 y 2 in the presence of diisopropylethylamine.
As another example of the interconversion process, compounds of formula containing a -CH 2
OH
group may be prepared by the reduction of corresponding compounds of formula containing a -CHO or -CO 2
R
7 (in which R 7 is lower alkyl) group. For example, the reduction may conveniently be carried out by means of reaction with lithium aluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature from about room temperature to about reflux temperature.
As another example of the interconversion process, compounds of formula in which R 2 is hydroxy may be prepared by reaction of the corresponding compounds of formula in which R 1 is methoxy with a Lewis acid, such as boron tribromide, in an inert solvent, such as dichloromethane and at a temperature from about 0°C to about room temperature.
As another example of the interconversion process, compounds of formula in which R 2 is -OR 4 (in which R 4 is optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl) may be prepared by alkylation the corresponding compounds of formula in which R 2 is hydroxy, with compounds of formula (XXX):-
R
4
-X
3
(XXX)
wherein R 4 is as just hereinbefore defined and X 3 is a halogen, preferably bromo, atom, or a tosyl group, using standard alkylation conditions. The alkylation may for example be carried out in the presence of a base, such as an alkali metal carbonate potassium carbonate or cesium carbonate), an alkali metal alkoxide potassium tertiary butoxide) or alkali metal hydride sodium hydride), in dimethylformamide, or dimethyl sulfoxide, at a temperature from about 0°C to about 1000C.
As another example of the interconversion process, compounds of formula in which R 1 is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, or alkyl substituted by -C(=O)NY 1
Y
2
-OR
7 -C(=0)-OR 7
-NY
1 y 2 may be prepared by alkylation of the corresponding compounds of formula (la) in which R 1 is hydrogen, with the appropriate halide of formula (XXXI):-
R
1
_X
4
(XXXI)
WO 03/000695 PCT/GB02/02835 -26wherein R 1 is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, or alkyl substituted by -C(=O)NYlY 2
-OR
7
-C(=O)-OR
7
-NY
1
Y
2 and X 4 is a halogen, preferably bromine, atom, using standard alkylation conditions for example those described hereinbefore.
As another example of the interconversion process, compounds of formula containing sulfoxide linkages may be prepared by the oxidation of corresponding compounds containing linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g.
3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature, or alternatively by means of potassium hydrogen peroxomonosulfate in a medium such as aqueous methanol, buffered to about pH5, at temperatures between about 0°C and room temperature. This latter method is preferred for compounds containing an acid-labile group.
As another example of the interconversion process, compounds of formula containing sulfone linkages may be prepared by the oxidation of corresponding compounds containing or sulfoxide linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.
As another example of the interconversion process, compounds of formula containing a cyano group may be prepared by reaction of the corresponding compounds of formula containing a -C(=O)-NH 2 group with phosphorus pentachloride in the presence oftriethylamine. The reaction may conveniently be carried out in an inert solvent, such as tetrahydrofuran, and at a temperature at about reflux temperature.
As another example of the interconversion process, compounds of formula containing a
-C(=O)-NH
2 group may be prepared by reaction of the corresponding compounds of formula (I) containing a cyano group with hydrogen peroxide in the presence of sodium hydroxide. The reaction may conveniently be carried out in methanol at a temperature at about room temperature.
As another example of the interconversion process, compounds of formula in which R 3 is -NY 1 y 2 (wherein Y 1 and Y 2 are as hereinbefore defined), may be prepared by reaction of the corresponding compounds of formula in which R 3 is halo chloro) with an amine of formula HNY 1 y 2 (wherein Y 1 and Y 2 are as immediately hereinbefore defined).
WO 03/000695 PCT/GB02/02835 -27- As another example of the interconversion process, compounds of formula in which R 3 is cyano may be prepared by reaction of compounds of formula in which X 1 is halo, preferably chloro, with zinc cyanide in the presence of zinc powder, [1'l-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex and dichloromethane (catalytic amount) and N,N-dimethylacetamide at a temperature up to about 150 0
C.
As another example of the interconversion process, compounds of formula containing a -C(=0)-OR 5 group (in which R 5 is as hereinbefore defined) may be prepared by reaction of the corresponding compounds of formula containing a-C(=O)-OH group with alcohols of formula
R
5 -OH. For example when R 5 is tert-butyl the reaction may conveniently be carried out in the presence of l-l'-carbonyldiimidazole and 1,8-diazabicyclo[5.4.0]undec-7-ene at a temperature at about room temperature.
It will be appreciated that compounds of the present invention may contain asymmetric centres. These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (I) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates.
According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
The acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.
WO 03/000695 PCT/GB02/02835 -28- Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.
Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.
According to a further feature of the invention, base addition salts of the compounds of this invention may be prepared by reaction of the free acid with the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compounds of this invention may be prepared either by dissolving the free acid in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free acid and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.
Intermediates of formula (XXVIII) wherein R 3 is as hereinbefore defined, X is iodo and the pyrrole NH is protected with a tosyl group may be prepared as shown in scheme 1.
SCHEME 1 R3
R
3
R
3 N N
N
H Tosyl Tosyl (XXXII) (XXXIII)
(XXXIV)
Thus for example compounds of formula (XXXIV) may be prepared by: reaction of compounds of formula (XXXII) with para-toluenesulfonyl chloride in the presence of aqueous sodium hydroxide and tetrabutyl ammonium sulfate in an inert solvent, such as toluene, and at room temperature; WO 03/000695 PCT/GB02/02835 -29- (ii) subsequent treatment of the resulting compound of formula (XXXIII) with butyl lithium in tetrahydrofuran, at a temperature at about -78°C; (iii) reaction of the resulting anion with iodine.
Intermediates of formula (XXXIII) wherein R 3 is heteroaryl may be prepared by reaction of compounds of formula (XXXIII) wherein R 3 is halo, e.g. chloro, with a borane of formula R 3 BEt 2 wherein R 3 is heteroaryl. The reaction may conveniently be carried out in the presence of tetrakis(triphenylphosphine)palladium(0) and potassium carbonate, in tetrahydrofuran at a temperature up to reflux temperature. This reaction is particularly suitable for the preparation of compounds of formula (XXXIII) wherein R 3 is pyridyl.
Intermediates of formula (XXXIII) wherein R 3 is heteroaryl may also be prepared by reaction of compounds of formula (XXXIII) wherein R 3 is halo, e.g. chloro, with heteroaryl-boronic acids of formula R 3 B(OH)2 in the presence oftetrakis(triphenylphosphine)palladium(0) and aqueous sodium bicarbonate, in dimethylformamide at a temperature up to reflux temperature. This reaction is particularly suitable for the preparation of compounds of formula (XXXIII) wherein R 3 is optionally substituted indolyl.
Intermediates of formula (XXXIII) wherein R 3 is OR 4 in which R 4 is as hereinbefore defined, may be prepared by reaction of compounds of formula (XXXIII) wherein R 3 is halo, e.g. chloro, with compounds of formula R 4 ONa (prepared by reacting alcohols of formula R40H with sodium) at a temperature up to about 65°C. This reaction is particularly suitable for the preparation of compounds of formula (XXXIII) wherein R 3 is OMe.
The present invention is further exemplified but not limited by the following illustrative Examples and Reference Examples.
High Pressure Liquid Chromatography Mass Spectrometry (LC-MS) conditions for determination of retention times (RT) were as follows:- Method A: Hypersil BDS C-18 column (4.6 mm x 50 mm) reverse phase operated under gradient elution conditions with mixtures of(A) water containing 0.05% trifluoroacetic acid and acetonitrile containing 0.05% trifluoroacetic acid as the mobile phase gradient (0.00 minutes 100%A:0%B; linear WO 03/000695 PCT/GB02/02835 gradient to 100% B at 2 minutes; then hold until 3.5 minutes); flow rate ImL/minute with approximately 0.25mL/minute split to the Mass Spectrometer; injection volume 10 gL; Hewlett Packard Model HP1100 Series UV detector wavelength 200nm; Evaporative light scattering (ELS) detection temperature 46 0 C, nitrogen pressure 4bar.
Method B: Gilson 215 injector model using a Hypersil HyPURITY C-18 -5 pL column (4.6 mm x mm) operated under gradient elution conditions with mixtures of water containing 0.05% trifluoroacetic acid and acetonitrile containing 0.05% trifluoroacetic acid as the mobile phase gradient: (0.00 minutes 95%A:5%B; linear gradient to 95% B at 4 minutes; then to 5% B at minutes, then hold until 6 minutes); injection volume 5 1 tL and flow rate ImL/minute to UV (DAD) detector followed by approximately 0.100mL/minute split to the Mass Spectrometer (positive electrospray) with remainder to ELS detector.
METHOD C: Micromass instrument model LCT linked to an HP 1100 model instrument. Compound abundance were detected using an HP model G1315A photodiode array detector in the 200-600 nm wavelength range and a Sedex model 65 evaporative light scattering detector. Mass spectra were acquired in the 180 to 800 range. Data were analysed using the Micromass MassLynx software.
Separation were carried out on a Hypersil BDS C18, 3 Rim particle size column (50 x 4.6 mm) eluted by a linear gradient of 5 to 90% acetonitrile containing 0.05% trifluoroacetic acid in water containing 0.05% trifluoroacetic acid in 3.5 minutes at a flow rate of 1 ml/minutc. The total runtime including column reequilibration was 7 minutes.
EXAMPLE 1 2-[5-Methoxy-3-(4-trifluoromethvl-7H-pyrrolo[2,3-b]pyrimidin-6-vl)-indol-l -vy- -morpholin-4-vlethanone 0 The compound of formula wherein R 1 is -CH N R 2 is -OMe, R 3 is -CF 3 the 0
R
3 group is attached to the 3 position of the indole ring and the group R 2 is
N
H
attached to the 5 position of the indole ring, represented by formula (II): WO 03/000695 WO 03/00695PCT/GB02/02835 -31is prepared as shown in the following scheme: N
H
(1) mCPBA NN
N
0 (2) Br P0Br3
N
TosCI, phase transfer KF, CulI ref I
CF,
N
KN
N
Tos
LDA
(ii) 12 Pd(O) 0S MeO
KOH
KN N \N Tos (7) MeO
CF
3 NN~ N K N N N HN 0 WO 03/000695 PCT/GB02/02835 32treatment of 7H-pyrrolo[2,3-b~pyrimidine with 3-chloroperbenzoic acid in dichioromethane at about 0 0 C to give 7H-pyfrolo[2,3-b]pyrimidine-N-oxide (ii) reaction of with phosphorous oxybromide at about 50'C to give 4-bromo-7Hpyrrolo[2,3J-b~pyrimidine (iii) reaction of with 4-toluene sulfonyl chloride in the presence of tetrabutylammonium sulfate and aqueous sodium hydroxide in toluene, to give 4-bromo-7H-pyrrolo[2,3b~pyrimidine (iv) reaction of with trifluoromethyltrimethylsilane in the presence of potassium fluoride and copper(J) iodide in dimethylformamide at about 60'C, to give 7-(toluene-4-sulfonyl)-4trifluoromethyl-7H-pyrrolo[2,3-b]pyrimidine treatment of with lithium diisopropylamide in tetraliydrofuran, at about -78'C, followed by reaction of the resulting anion with iodine to give 6-iodo-7-(toluene-4-sulfonyl)-4trifluoromethyl-7H-pyrrolol2,3-blpyrimidine (vi) coupling of with 1-tert-butyloxycarbonyl-5-rnethoxy-1H-indole-3-boronic acid in the prcscncc of tctrakis(triphenylphosphinc)palladium(O) and sodium bicarbonate, in aqueous dimethylformamide at about reflux temperature and removal of the tert-butyloxycarbonyl protecting group followed by treatment with methyl iodide in the presence of sodium hydride, in tetrahiydrofuran, to give 6-(5-methoxy- IH-indol-3-yl)-7-(toluene-4-sulfonyl)-4trifluoromethyl-7H-pyrrolo[2,3-bjpyrimidine (viii) removal of the tosyl protecting group in by treatment with potassium hydroxide in methanol to give 6-(5-methioxy- 1H-indol-3-yl)-4-trifluoromethiyl-7H-pyrrolo[2,3-b]pyrimidine and (ix) alkylation of with 4-(2-chloroacetyl)morpholine in the presence of sodium hydride, in dimethylformamide to give 2-[5-methoxy-3-(4-trifluoromethyl-7H-pyrrolol2,3-blpyrimidin-6yl)-indol-1I-yl]- 1-morpholin-4-yl-ethanone EXAMPLE 2 1 -Methyl-3-(7H-pyrrolor2,3-blpyrimidine-6-vl)-1 H-indole-5-carboxylic acid (2-hydroxy-1 .1-dimethylethyI -amide WO 03/000695 PCT/GB02/02835 -33- 0 Me Me The compound of formula wherein R 1 is -CH 3
R
2 is CH OHR 3 is -H the group
H
R
3 is attached to the 3 position of the indole ring and the group R 2 is attached to N N
H
the 5 position of the indole ring, represented by formula (III): is prepared as shown in the following scheme: WO 03/000695 PCT/GB02/02835 34-
N
Hts ts
HO-~B/
h ,zzCOCH, Na 0 2 H COCH, N N N N CH 3
H
(14) (13)
IN
CH
H H 3 (111) reaction of with 4-toluene sulfonyl chloride in the presence of tetrabutylammonium sulfate and aqueous sodium hydroxide in toluene, to give (ii) treatment of (10) with lithium diisopropylamide in tetrahydrofuran, at about -78'C, followed by reaction of the resulting anion with iodine to give (11); (iii) coupling of (1 1) with 1-tert-butyloxycarbonyl-5-methoxy-IH-indole-3-horonic acid (12) in the presence of tetrakis(triphenylphosphine)palladium(0) and sodium bicarbonate, in aqueous dirnethylformamide at about reflux temperature and removal of the tert-butyloxycarbonyl protecting group followed by treatment with methyl iodide in the presence of sodium hydride, in tetrahydrofuran, to give -methyl-5-carbomethoxyindole)3-yljj-7H-pyrrolo[2,3b]pyrimidine (13); (iv) treatment of (13) with aqueous methanolic potassium hydroxide at reflux to give methy1-5-carboxyindole)3-yl]-7H-pyrrolo[2,3-b~pyrimidine and WO 03/000695 PCT/GB02/02835 coupling of (14) with 2-hydroxy- 1,1 -dimethylethylamine in the presence of O-(7-azabenzotriazol- l-yl)-1,l,3 ,3-tetramethyluronium hexafluorophosphate and diisopropylethylamine in diniethylformamide to give I -methyl-3-(7H-pyrrolo[2,3b]pyrimidine-6-yl)-1 H-indole-5-carboxylic acid (2-hydroxy- 1, -dimethyl-ethyl)-amide (111).
EXAMPLE 3 2.4[5-Methoxvy-3-(711-pyrroloF23-blpvrimidine-6-vl)-indol- 1-l1-1I-morpholin-4-yI I-ethanone 0 The compound of formula wherein RI is -CH A N R 2 is -OMe, R 3 is the group 0
N
N
N
H is attached to the 3 position of the indole ring and the group R 2 is attached to the S position of the indole ring, represented by formula (IV):
H
0- No 0
(IV)
is prepared as shown in the following schemne: WO 03/000695 WO 03/00695PCT/GB02/02835 36ts O H
HO-B'
OMe Na boo 0
NN
N 0N N -N N H H H 0 No(17) 0
(IV)
coupling of 6-iodo-7-(toluene-4-sulfonyl)-7H-pyrroio[2,3-b]pyrimidine (11) 1 -tertbutyloxycarbonyl-5-methoxyindole-3-boronic acid (15) in the presence of tetrakis(triphenylphosphine)palladium(O) and sodium bicarbonate, in aqueous dimethylformam-ide at about reflux temperature and removal of the tert-butyloxycarbonyl protecting group, to give 6-[(5-methoxyindole)-3-yl]-7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3bjpyrimidine (16); treatment of (16) with aqueous methanolic potassium hydroxide at reflux to give methoxyindole)3-yl]-7H-pyrrolo[2,3-b]pyrimidine and (iii) reaction of (17) with sodium hydride in dimethylformamide followed by reaction with 2bromoacetic acid morpholineamide to give 2- {[5-methoxy-3-(7H-pyrrolo[2,3)-b]pyrimidine-6yl)-indol- l-yl]-l -morpholin-4-yl}-ethanione (IV).
WO 03/000695 PCT/GB02/02835 -37- EXAMPLE 4 The compound of formula wherein R 1 is -CH 2
CF
3
R
2 is -OMe, R 3 is-CN, the group
R
3 N is attached to the 3 position of the indole ring and the group R 2 is attached to N
N
H
the 5 position of the indole ring, represented by formula (VII): MeO
CN
N
H
CF
3
(VII)
is prepared as shown in the following scheme: WO 03/000695 PCT/GB02/02835 38- NaOEt EtO M~ ort tOB IN EtOH NC~CO~EI Hal H,1N NH-, NS' N NH, (21) r Br Br0 K'12, LDATHF TasCI PO~r, H N ~N NI(HF N HN Tos Tos (24) (23) (22) me MeO MeO Br Zn(CN) 2 Er CF 3
CH
2 1 Br Pd N DMA, 140 C N N ,N N, NaH, THF K' I Tos Tos 13TS l (26) (27) (28) IKOH MeOH MeD
N
(VII)
reaction of (18) and (19) in the presence of potassium carbonate and sodium iodide to give (ii) reaction of (20) with thiourea in the presence of sodium ethoxide in ethanol to give (21); (iii) cyclisation of (21) by heating in toluene at about reflux to give (22); (iv) reaction of (22) with phosphorus oxybromide to give 4-bromo-7H-pyrrolo[2,3b]pyrimidine (23); reaction of (23) with 4-toluenesulfonyl chloride in the presence of tetrabutylanmmonium sulfate and aqueous sodium hydroxide in toluene to give (24); WO 03/000695 PCT/GB02/02835 -39- (vi) treatment of(24) with lithium diisopropylamide in tetrahydrofuran, at about -78 0
C,
followed by reaction of the resulting anion with iodine to give (vii) coupling of (25) with 1-tert-butyloxycarbonyl-5-methoxyindole-3-boronic acid in the presence oftetrakis(triphenylphosphine)palladium(0) and sodium bicarbonate, in aqueous dimethylformamide at about reflux temperature and removal of the tert-butyloxycarbonyl protecting group, to give 4-bromo-6-[(5-methoxyindole)3-yl]-7-(toluene-4-sulfonyl)-7Hpyrrolo[2,3-b]pyrimidine (26); (viii) reaction of (26) with sodium hydride in tetrahydrofuran followed by reaction with 2trifluoro-iodoethane to give (27); (ix) reaction of (27) with zinc cyanide in the presence of palladium in N'N-dimethylaniline at about 140 0 C to give and treatment of (28) with aqueous methanolic potassium hydroxide at reflux to give (VII).
EXAMPLE O Me Me The compound of formula wherein R 1 is -CH 3
R
2 is -OMe, R 3 is N CH2OH, the H 2
R
3 group is attached to the 3 position of the indole ring and the group R 2 is N
N
H
attached to the 5 position of the indole ring, represented by formula (IX):
CH
2 O H MeO N N N
H
WO 03/000695 WO 03/00695PCT/GB02/02835 is prepared as shown in the following scheme: MeO MeG Br 7Br O 'rH Cj Me[, NaH PdNefu K X NH
N,
Tos Tos
CH
2
OH
MeG' 0 N1H
N
HN-
)H
HATU
DIPEA
DMP
(NX
(ii) reaction of (26) with sodium hydride in tetrahydrofuran followed by reaction with methyl iodide to give (29); (ii) reaction of (29) with carbon monoxide in the presence of palladium in methanol at reflux to give (iii) treatment of (30) with aqueous methanolic potassium hydroxide at reflux to give (3 and (iv) coupling of (3 1) with 2-hydroxy-1,l-dimethylethylamine in the presence of O-(7-azabenzotriazol-1I-yl)-1 ,I,3 ,3-tetramethyluronium hexafluorophosphate and diisopropylethylamine in dirnethylformamide to give (TX).
WO 03/000695 PCT/GB02/02835 41- EXAMPLE 6 0 The compound of formula. wherein R 1 is -CHA N ,R 2 is -OMe, R 3 is 0
R
3 0N
N
the group H is attached to the 3 position of the indole ring and the group R 2 is attached to the 5 position of the indole ring, represented by formula is prepared as shown in the following scheme: MeO OCMe me NH Heck
\N\
Tos Tos (32) Pd/c
H
2 MeNH 2 H4ATLJ
D/PEA
DMF
I KOH 5N, MeOH CONHIA9 Meo N NaH-, THF WO 03/000695 PCT/GB02/02835 -42reaction of (26) with methyl acrylate in the presence of palladium acetate, triphenyl phosphine and triethylamine at about 110 0 C to give (32); (ii) hydrogenation of(32) in the presence of palladium on carbon to give (33); (iii) treatment of (33) with aqueous methanolic potassium hydroxide at reflux to give the acid (34); (iv) coupling of (34) with methylamine in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate and diisopropylethylamine in dimethylformamide to give and alkylation of (35) with 4-(2-chloroacetyl)morpholine in the presence of sodium hydride, in dimethylformamide to give EXAMPLE 7 0 The compound of formula wherein R 1 is -CH N R 2 is-OMe, R 3 is
R
3 the group is attached to the 3 position of the indole ring and N N
H
the group R 2 is attached to the 5 position of the indole ring, represented by formula (VI): WO 03/000695 WO 03/00695PCT/GB02/02835 is prepared as shown in the following scheme: MeO Br Tos (28)
'CH
DMF, reflux aq. Na 2
CO'
Pd(P~h3) 4 I KOH 5N, MeO- Me 0 0 coupling of (26) with pyridine-3-boronic acid in the presence of tetrakis(triphenylphosphine)palladium(O) and sodium bicarbonate, in aqueous dimethylformamide at about reflux temperature to give 4-(pyridin-3-yl)-6-[(5methoxyindole)3-yl]-7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-b]pyrimidine (36); (ii) treatment of (36) with aqueous methanolic potassium hydroxide at reflux to give (37, Example and WO 03/000695 PCT/GB02/02835 44- (iii) alkcylation of (37, Example 9) with 4-(2-chloroacetyl)morpholine in the presence of sodium hydride, in dimethylformamide to give 2-[5-methoxy-3-(4-(pyridin-3-yl)-7H-pyrrolo[2,3b]pyrimidin-6-yl)-indol-1I-yll- I-morpholin-4-yl-ethanone (VI).
EXAMPLE 8 The compound of formula wherein RI is -CH4 2
CH
3
R
2 is -OMe, R 3 is ,the group k- R 3 I is attached to the 3 position of the indole ring and the group R 2 is attached to N
N
H
the 5 position of the indole ring, represented by formula (Vill): C) OMe
'NN
NN
(Vill) is prepared as shown in the following scheme: MeO MeO Br Br Eti, NaH
N
NI N, Tos TosS (26) (38) 0 Meo Meo K. (Vill) (39) WO 03/000695 PCT/GB02/02835 alkylation of (26) with ethyl iodide in the presence of sodium hydride, in dimethylformamide to give (3 8); (ii) reaction of (3 8) with morpholine in a microwave oven at about 200'C in c*(XcLtrifluorotoluene to give and (iii) treatment of (39) with aqueous m-ethanolic potassium hydroxide at reflux to give (VIII).
EXAMPLE 9 6-(5-Methoxy-1 H-indol-3-vhl-4-pyridin-3-yl-7H-pyrrolo)[2,3-dlpvrimidine
HH
A solution of 6-iodo-7-[(4-methylphenyl)sulfonyl]-4-pyridin-3 -yl-7H-pyrrolo[2,3-d]pyrimidine [260mg, Reference Example 1] and 1 -tert-butyl-carboxyl-5-methoxy- IH-indole-3-boronic acid [178mg, Reference Example 12] in dimethylformamide (1 OmL) was treated with palladium tetrakis triphenyl phosphine (13mg) and sodium hydrogen carbonate (8mg). The reaction mixture was stirred at reflux for 2 hours and allowed to cool to room temperature. The solution was evaporated under reduced pressure and the residue partitioned between water and ethyl acetate. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and methanol (95:5, v/v) to give 6-(5-Methoxvy- I H-indol-3-fl-4-pvridin-3-yl-7H-pyrrolo[2,3-dlpyrimidine as an amorphous solid. MS: 342 LCMS (Method A) RT 2.57 minutes.
EXAMPLE 4-Methoxy-6-(5-methoxy- I-methyl-i H-indol-3-yl)-7H-pvrroloI 22 -dinyrimidine WO 03/000695 PCT/GB02/02835 46- Meo Ome Na N
\N
A solution of 4-methoxy-6-(5-methoxy- 1-methyl-i H-indol-3-yl)-7-[(4-methylphenyl)sulfonyll-7Hpyrrolo[2,3-d]pyrimidine [361mg, Reference Example 4] in methanol (2OmL) was treated with potassium hydroxide (1 .53g). The reaction mixture was stirred for 16 hours at room temperature and refluxed 1 hour. The solution was evaporated under reduced pressure and the residue partitioned between water and ethyl acetate. The organic phase was separated, then dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with diethyl ether to give 4-methoxv-6-(5-methoxv-1-inethyl-I H-indol-3-vyl)-7HVyrrolo[2,3-dlpyrimidine (155mg) as a solid m.p. =184*C. MS: 309 EXAMPLE I I 4-Methoxy-6-(5-methoxy- I H-indol-3-yl)-7H-:pvrrolo[2,3-dlpvrimidine 1Meo Ome
N
N H
H
A solution of 4-methoxy-6-(5-methioxy- 1H-inidol-3 -yl)-7-[(4-methylplhenyl)sulfoniyl]-7H-pyrrolo[2,3d]pyrimidine [448mg, Reference Example 5] in methanol (1 5mL) was treated with potassium hydroxide (I1.96g). The reaction mixture was stirred for 2 hours at room temperature and the solvent was evaporated under reduced pressure. The residue was partitioned between water and ethyl acetate.
The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (8 0:20, v/v) to give 4-methoxv-6-(5-methoxy-1 H-indol-3-y1)- 7H-pvrroloF2,3-dlnvrimidine (320mg) as a yellow solid m.p. 260'C. MS: 295 [IVH]+.
EXAMPLE 12 1H-indol-3-vh)-6-(5-mnethoxv-1I-methyl- IH-indol-3-vh)-7H-Dvrrolor2-3-dluvrimidinie WO 03/000695 PCT/GB02/02835 -47-
H
N MeO MeO N Me
H
A solution of 4-(5-methoxy-1 [(4-methylphenyl)sulfonyl]- 1H-indol-3-yl)-6-(5-methoxy- 1-methyl-1FHindol-3-yl)-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine [93mg, Reference Example 9] in methanol (5mL) was treated with potassium hydroxide (249mg). The reaction mixture was stirred for 16 hours at room temperature. The solution was evaporated under reduced pressure and the residue partitioned between ethyl acetate and water. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was purified by HPLC to give 4-(5-methoxy-1H-indol-3-vl)-6-(5-methoxv-l-methyl-1H-indol-3-vly-7H-pyrrolo[2.3-d]pyrimidine (9mg) as a gum. MS: 424 [MH] LCMS (Method B) RT 3.15 minutes.
REFERENCE EXAMPLE 1 6-Iodo-7-[(4-methylphenvl)sulfonvll-4-pyridin-3-vl-7H-pyrrolo[2,3-d]pvrimidine To a solution of 7-[(4-methylphenyl)sulfonyl]-4-pyridin-3-yl-7H-pyrrolo[2,3-d]pyrimidine [1g, Reference Example 2] in tetrahydrofuran (20mL) at -78 0 C was added drop wise a solution of butyl lithium in hexane (2mL, 1.6M) under inert atmosphere. The solution was stirred at that temperature for hour and iodine (796mg) was added. The reaction mixture was stirred at -78°C for another 1 hour and allowed to reach room temperature. The reaction mixture was partitioned between ethyl acetate and aqueous sodium sulfite solution. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a gradient of ethyl acetate and cyclohexane (50:50, to 100, v/v) to give the title compound (260mg) as an amorphous solid. MS: 477 [MH] LCMS (Method B) RT 3.26 minutes.
REFERENCE EXAMPLE 2 7-f(4-Methylphenvl)sulfonvl]-4-pyridin-3-yl-7H-pyrrolo[2,3-d1pyrimidine A solution of 4-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine [4g, Reference Example 3] and diethyl-3-pyridyl-borane (2.1g) in tetrahydrofuran (180mL) was treated with palladium tetrakis triphenylphosphine (0.65g) and potassium carbonate (3.59g). The solution was stirred at reflux for 24 hours and evaporated under reduced pressure. The residue was partitioned between ethyl acetate and brine. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected twice to flash column chromatography on silica WO 03/000695 PCT/GB02/02835 -48eluting with a mixture of ethyl acetate and methanol (90:10, v/v) and a mixture of ethyl acetate and cyclohexane (50:50, v/v) to give the title compound (2.5g) as an amorphous solid. MS: 351 [MH] LCMS (Method B) RT 3.05 minutes.
REFERENCE EXAMPLE 3 4-Chloro-7-[(4-methylphenvl)sulfonyll-7H-pyrrolo[2,3-dlpyrimidine A solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (Reference: Gerster, John F. Hinshaw, Barbara Robins, Roland Townsend, Leroy B. Study of electrophylic substitution in the pyrrolo[2,3d]pyrimidine ring. J. Heterocycl. Chem. (1969), 207-213) (20g) andpara-toluene sulfonylchloride (28.6g) in toluene (1L) was treated with a solution of sodium hydroxide (50g) in water (800mL), and tetrabutyl ammonium sulfate (462mg). The solution was stirred vigorously at room temperature for 2 hours and partitioned between ethyl acetate and brine. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a gradient of ethyl acetate and cyclohexane (50:50 to 80:20, v/v) to give the title compound (2.5g) as a solid m.p. 143°C. LCMS (Method B) RT 2.78 minutes.
REFERENCE EXAMPLE 4 4-Methoxy-6-(5-methoxy- 1-methyl-1 H-indol-3-yl)-7-[(4-methylphenyl)sulfonyll-7Hpyrrolo[2.3 dpyrimidine To a solution of 4-methoxy-6-(5-methoxy- H-indol-3-yl)-7-[(4-methylphenyl)sulfonyl]-7Hpyrrolo[2,3-d]pyrimidine [448mg, Reference Example 5] in dimethylformamide (20mL) was added the sodium hydride (44mg, 60% dispersion in oil) and methyl iodide_(156mg) under inert atmosphere. The solution was stirred for 1 hour at room temperature and the solvent was evaporated under reduced pressure. The residue was partitioned between water and ethyl acetate. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (30:70, v/v) to give the title compound (260mg) as an amorphous solid. MS: 464 [MH LCMS (Method B) RT 4.39 minutes.
REFERENCE EXAMPLE 4-Methoxy-6-(5-methoxv-lH-indol-3-yl)-7-r(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine A solution of 6-iodo-4-methoxy-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine [1.98g, Reference Example 6] and 1-tert-butyl-carboxyl-5-methoxy-lH-indole-3-boronic acid [1.26g, Reference Example 12] in dimethylformamide (40mL) was treated successively with a saturated aqueous solution of sodium bicarbonate (10mL) and palladium tetrakis triphenylphosphine (165mg).
WO 03/000695 PCT/GB02/02835 -49- The reaction mixture was stirred at reflux for 3 hours and the solvent was evaporated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (50:50, v/v) to give the title compound (1.8g) as a grey solid. 131 0 C. MS: 450
[MH]
REFERENCE EXAMPLE 6 6-Iodo-4-methoxv-7-[(4-methylphenyl)sulfonyll-7H-pyrrolo[2,3-dlpyrimidine To a solution of 4-methoxy-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine [2.23g, Reference Example 7] in tetrahydrofuran (35mL) at -78 0 C was added drop wise a solution of butyl lithium in hexane (5mL, 1.6M) under inert atmosphere. The solution was stirred at -70 0 C for 1 hour and iodine (2.05g) was added. The reaction mixture was stirred at -70 0 C for another 1 hour, allowed to reach room temperature and partitioned between ethyl acetate and aqueous sodium sulfite solution. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure to give the title compound (2.64g) as an amorphous solid. MS: 430 [MH] LCMS (Method B) R T 4.15 minutes.
REFERENCE EXAMPLE 7 4-Methoxy-7-[(4-methylphenvyl)sulfonvl]-7H-pvrrolo[2,3-dlpvrimidine A solution of 4-methoxy-7H-pyrrolo[2,3-d]pyrimidine [1.2g, Reference Example 8] and para-toluene sulfonylchloride (1.77g) in toluene (60mL) was treated with a solution of sodium hydroxide (3.2g) in water (30mL), and tetrabutyl ammonium sulfate (27mg). The solution was stirred vigorously at room temperature for 4 hours and partitioned between ethyl acetate and brine. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a gradient of ethyl acetate and cyclohexane (50:50 to 80:20, v/v) to give the title compound (2.23g) as an amorphous solid. MS: 304 [MH] LCMS (Method B) RT 3.88 minutes.
REFERENCE EXAMPLE 8 4-Methoxv-7H-pvrrolof2,3-dl primidine To a solution of sodium methoxide prepared by adding portion wise the sodium (2g) in methanol (100mL) under an inert atmosphere, was added 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (Reference: Gerster, John F. Hinshaw, Barbara Robins, Roland Townsend, Leroy B. Study of electrophylic substitution in the pyrrolo[2,3-d]pyrimidine ring. J. Heterocycl. Chem. (1969), 207-13.) The solution was stirred at 65 0 C for 16 hours and then partitioned between ethyl acetate and brine.
WO 03/000695 PCT/GB02/02835 The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (50:50, v/v) to give the title compound (1.2g) as an amorphous solid. MS: 150 LCMS (Method B) RT= 2.39 minutes.
REFERENCE EXAMPLE 9 4-(5-Methoxv-1 -F(4-methylnhenvl)sulfonvl]-1IH-indol-3-vl)-6-(5-methoxv-1-methyl-l H-indol-3-vl)-7- (4-methvlphenvl)sulfonvll-7H-pvrrolol2,3-dlpvrimidine To a solution of 4-(5-methoxy-1 -[(4-methylphenyl)sulfonyl]-IH-indol-3-yl)-6-(5-methoxy-1H-indol-3yl)-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine [270mg, Reference Example 10] in dimethylformamide (1 OmL) was added the sodium hydride (10mg, 60% dispersion in oil) and methyl iodide (0.025mL) under inert atmosphere. The solution was stirred for 16 hours at room temperature and the solvent was evaporated under reduced pressure. The residue was partitioned between water and ethyl acetate The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (50:50, v/v) to give the title compound (93mg) as an amorphous solid. MS: 732 [MH] LCMS (Method B) RT 4.68 minutes.
REFERENCE EXAMPLE 4-(5-Methoxy- 1 -[(4-methylphenvDl)sulfonvl]- 1 H-indol-3-vl)-6-(5-methoxy-IH-indol-3-vl)-7-[(4methvlphenvl)sulfonvll-7H-pvrrolor2,3-dlpvrimidine A solution of 4-chloro-6-iodo-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine [1.72g, Reference Example 11] and 1 -tert-butyl-carboxyl-5-methoxy-1H-indole-3-boronic acid [1.26g, Reference Example 12] in dimethylformamide (36.5mL) was treated successively with a saturated aqueous solution of sodium bicarbonate (9.lmL) and palladium tetrakis triphenylphosphine The reaction mixture was stirred at reflux for 2 hours and the solvent was evaporated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic phase was separated, then dried over magnesium sulfate and then evaporated under reduced pressure. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (30:70, v/v) to give the title compound (270mg) as a gum. MS: 718 LCMS (Method B) RT 4.44 minutes.
REFERENCE EXAMPLE 11 4-Chloro-6-iodo-7-fr(4-methvlnhenvllsulfonvll-7H-ovrrolof2.3-dlnovrimidine WO 03/000695 PCT/GB02/02835 51- To a solution of 4-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine [5.4g, Reference Example in tetrahydrofuran (96mL) at-78°C was added drop wise a solution of butyl lithium in hexane (12.1mL, 1.6M) under inert atmosphere. The solution was stirred at -78 0 C for 3 hours and iodine (8.9g) was added. The reaction mixture was stirred at -78 0 C for 2 hours, and allowed to reach room temperature. The reaction mixture was partitioned between ethyl acetate and aqueous sodium sulfite solution, dried over magnesium sulfate and the solvent was evaporated under reduced pressure.
The residue was subjected to flash column chromatography on silica eluting with a gradient of ethyl acetate and cyclohexane (50:50, to 100, v/v) to give the title compound (1.52g) as an amorphous solid.
MS: 434 [MH] LCMS (Method B) RT 4.26 minutes.
REFERENCE EXAMPLE 12 1H-indole-3-boronic acid A stirred solution of 3-bromo-5-methoxy-indole-1-carboxylic acid, tert-butyl ester [50g, Reference Example 13)] in tetrahydrofuran (800 mL), under nitrogen, was treated with tributylborate (49.5 mL) then cooled to -100 0 C and then treated with a solution of n-butyllithium in hexanes (94 mL, whilst keeping the temperature below -90 0 C. Once the addition was complete the mixture was allowed to warm slowly to room temperature over 1 hour and quenched by the addition of ice (10g). The organics were removed under reduced pressure and the residue was partitioned between ethyl acetate (500 mL) and water (400 mL). The organic layer was dried over magnesium sulfate and then evaporated to afford the title compound as a cream coloured solid (28g). MS: 314 [M+Na] LCMS (Method C) RT 4.07 minutes.
REFERENCE EXAMPLE 13 -carboxylic acid, tert-butvl ester A solution of 5-methoxyindole (10g) in dry dimethylformamide (150 mL) at ambient temperature was treated with bromine (4 mL) dropwise ensuring the temperature did not rise above 30 0 C. The mixture was treated immediately with triethylamine (28 mL) and 4-dimethylaminopyridine (0.5g) followed by a solution of di-tert-butyldicarbonate (18g) in dry dimethylformamide (80 mL) and stirring was continued for a further 4 hours. The reaction mixture was evaporated and the residue was partitioned between ethyl acetate (250 mL) and water (200 mL). The aqueous layer was extracted with ethyl acetate (100 mL). The combined organic phases were washed with water (100 mL), then with brine (100 mL), then dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of pentane and ethyl acetate (19/1, v/v) to give the title compound (23.
4 g) as a colourless solid, m.p. 111-112 0
C.
WO 03/000695 PCT/GB02/02835 -52- IN VITRO TEST PROCEDURES FOR SYK 1. Inhibitory effects of compounds on Syk kinase Inhibitory effects of compounds on Syk kinase were determined using a time-resolved fluorescent assay.
The catalytic domain of Syk kinase (residues A340-N635 was expressed as a fusion protein in yeast cells and purified to homogeneity. Kinase activity was determined in 50mM Tris-HCl buffer pH containing 50mM NaCI, 5mM MgCl 2 5mM MnCl 2 1M adenosine triphosphate and 10 M synthetic peptide Biotin-( 3-Alanine) 3 -DEEDYEIPP-NH2. Enzyme reactions were terminated by the addition of buffer containing 0.4M KF, 133mM EDTA, pH 7.0, containing a streptavidin-XL665 conjugate and a monoclonal phosphospecfic antibody conjugated to a europium cryptate Features of the two fluorophores, XL-665 and Eu-K are given in G.Mathis et al., Anticancer Research, 1997, 17, pages 3011-3014. The specific long time signal of XL-665, produced only when the synthetic peptide is phosphorylated by Syk, was measured on an LJL Biosystems Analyst AD microplate reader. Inhibition of syk activity with compounds of the invention was expressed as percentage inhibition of control activity exhibited in the absence of test compounds. Particular preferred compounds of the invention inhibit syk activity with IC 5 0 s in the range 100 micromolar to 100 nanomolar. Especially preferred compounds of the invention inhibit syk activity with IC 5 0 s in the range 1 micromolar to 100 nanomolar.
2. Antigen-induced degranulation of Rat Basophilic leukemia (RBL) cells 2.1 Cell culture, labelling of RBL-2H3 cells and performance of assay.
RBL-2H3 cells are maintained in T75 flasks at 37 0 C and 5%CO 2 and passaged every 3-4 days. To harvest cells, 5 ml trypsin-EDTA is used to rinse the flask once, then 5 ml trypsin is added to each flask, and incubated at room temperature for 2 minutes. Cells are transferred to a tube with 14ml medium, spun down at 1100 rpm RT for 5 minutes and resuspended at 2x10 5 /ml. Cells are sensitized by adding Ip1 of DNP-specific IgE to every 10 ml of cells. 200.l of cells are added to each well of a flat-bottom 96 well plate (40,000 cells/well), and the plate incubated overnight at 37 0 C and 5%C0 2 The next day compounds are prepared in 100% DMSO at 10mM. Each compound is then diluted 1:100 in assay buffer and then diluted further in 1% DMSO-assay buffer to obtain final concentrations of 0.03-30piM. 80gl assay buffer is added to each well, followed by 10.1 of diluted compound.
Incubation follows for 5 minutes. 10tl of DNP-HSA (100ng/ml) is added to each well and incubated 10-Dec-2008 17:03 Watermark +61298887600 10/38 00 53 0 Sat 37°C (no CO 2 for 30 minutes. As one control, 1% DMSO alone (no compound) is added to a 0, set of wells to determine total release. As another control, add buffer instead of DNP-HSA to 0 another set of wells to determine the assay background. After the 30 minutes incubation, the o supernatants are transferred to a new 96-well plate. Add 50P1 supernatant to each well of an assay plate. Add lOO1gl of substrate solution to each well and incubate at 37°C for 90 minutes. Add 501 of 0.4 M glycine solution to stop the reaction and the plate is read at 405 in on a Molecular Devices SpcctraMax 250 plate reader.
S2,2 Calculation of results 0 S(i) The mean SD of each set of triplicate wells was calculated.
(ii) Maximum response was the positive control wells containing antigen (10Ong/mnL) but no compound, (iii) Minimum response was the control wells containing buffer (no antigen) and no compound.
(iv) Using these values as the maximum (100%) and minimum values respectively, the experimental data was calculated to yield a percentage of the maximum response (designated control).
A dose response curve was plotted and the IC 50 of the compound was calculated using Prism GraphPad software and nonlinear least squares regression analysis.
Compounds of the invention inhibit antigen-induced degranulation of Rat Basophilic leukemia (RBL) cells with EC 50 s in the range 100 mioromolar to 1 mieromolar.
Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10
Claims (12)
10-Dec-2008 17:04 Watermar-k +61298887600 11/38 00 oTWE CLANMS DEFININGy TIll? IVENTION ARE AS FOLLOWS: S1. A compound of the formula 0 3 RR iwhere/n RI iirsnshdoe,-(O-NI2,-(O-)5 S2N1Y,-O-7 C-)7 RIrprsns lcnyl leyoy lyak nl rl eerayhtrccolycwolclo d ereentschgn -CHO(= O)-NYlY 2 S0 -NYY 2 K 7 -CO)R 7 RIox rersnts caileyl.aknlx;akl lyy yhtrayhtrccolcl ylaklo Ry2lalklplylseac pinaltustttdb one or more groups selected from hydrge, cyclaslkylendoy ley, l eyoy ak nl rl cyano, halo, y rx, heteroaryl, heterocycloalkyl, niCEO or a o e bee ylc scs derivativey2 ofsc -CEO,5 -&)Ny 1 Y 2 -C&O6)-0R 5 -NY Y, -N(R 6 -N(R 6 -N(R-S0 2 -R7, -N(R 6 )-50 2 -NY3Y4, -OR 7 ,~lY -and-R 7 hyroy K3 represents ony, etororegoup slenlece frmhdognrl alkylenec ptoalysbsiuedxy, ilenymor slenlecyd arokynyly, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, A,) -C&y')-NY'Y 2 O, NY'Y 2 -N(R, 6 7 -N(R 6 )-C=O)-yRy, NKyCO0R,-N( R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -NY 3 y 4 -50 2 -NY 1 Y 2 and -ZR 4 K5 3 R represents alyl, lctryclalkeyl or lokalkyl, each optionally substituted by one or more groups selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, hydroxy, -CEO COMS IDNo: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10 l0-Dec-2008 17:05 Watermark +61298887600 12/38 00 O or a 6- or 7-ruembered cyclic acetal derivative of such -C&=O)-NY'Y 2 oNY 1 Y 2 -N(R 6 N(R 6 -N(R 6 )-S0 2 -R 7 -N(R 6 )-S0 2 -Ny 3 y4, 0 OR 7 and 7 [[where R 4 is optionally interspersed with a group selected from 0, S(0)n, 0 and NR 6 11; R 5 represents hydrogen, alkyl, aikenyl, aryl, arylailcyl, heteroaryl or heteroarylalcyl; 11TR6 represents hydrogen or lower al~kyl; Cfl R 7 represents alkyl, aryl, arylailcy], cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalk, heterocycloalcyl or heterooycloaklalcl; R8represents hydrogen or lower ak]; Y 1 and Y 2 are independently hydrogen, alcnyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, hydroxy, -C(=O)-NY 3 Y 4 5 -NY 3 Y 4 -N(R 6 7 -N(R 6 3 y4, -N(R 6 )-50 2 -R7, -N(R 6 )-S0 2 NY 3 Y4 and -OR 7 or the group -NY 1 Y 2 may form a cyclic amine; y 3 and Y 4 are independently hydrogen, alkenyl, ailkyl, aryl, arylalkyl, cycloalkyl, heteroaryl. or eteroarylalcyl; or the group -NY 3 Y 4 may form a cyclic amine; Z reprecsents 0 Or S(O)n; n is zero or an integer 1 or 2; or an N-oxide, an acid bloisostere selected from the group consisting of:- -C(=O)-NI{IOI-I, CH01I -C&0O)-CH 2 SH, aulfo, phosphono, alkcylsulfonylcarbamoyl, tetrazolyl, arylsulfonylearbamnoyl, hcteroarylsulfonylcarbainoyl, N-methoxycarbamoyl, 3-hydr-oxy-3- cyclobuitene-l ,2-dione, 3,5-dioxo-1 ,2,4-oxadiazolidinyl, 3-hydroxyisoxazolyl and 3-hiydroxy-l -methylpyrazolyl; a pharmaceutically acceptable salt of such compound; or an N- oxide, or acid bioisositere selected from the group consisting of: 2 011, -CQ=Q)-CH2?SH, -CQQ)-NI-I-CNh, sulfo, phosphono, alkylsulfonylcarbamoyl, tetrazolyl, arylsulfony~carbamoyl, heteroarylsulfonylcaxbainoyl, N-methoxycarbamoyl, 3-hydroxy-3- cyclobutenie-l ,2-dione, 3,5-dioxo-l ,2,4-oxadiazolidinyl, 3-hydroxyisoxazolyl and 3-hydoxy-l -methylpyrazolyl; of such salt, 2. A compound according to claim 1 wherein RI is hydrogen, C 1 4 alkyl, CI-4alkyl substituted by halo, C 1 4 alkyl substituted by hydroxy, Cj. 4 allcyl substituted by -N(R 6 7 Cl~alkyl substituted by -C&OQ)-NY 1 Y 2 or cycloalcylalkl substituted by hydroxy. COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10 10-Dec-2008 17:06 Watermark +61298887600 13/38 00 56 O 0 O 3. A compound according to claim I wherein RI is hydrogen, -CH3, -CH2CH3, -CH 2 CF 3 or -CH 2 -N o en4. A compound according to claim 1 wherein RI is hydrogen. n 5 5. A compound according to claim 1 wherein R2 is carboxy or an acid bioisostere selected from the group consisting of: -C(=O)-NHOH, -C(=O)-CH2SH, sulfo, phosphono, alkylsulfonylearbamoyl, tetrazolyl, arylsulfonylcarbamoyl, heteroarylsulfonylcarbamoyl, N-methoxycarbaioyl, 3 -hydroxy-3-cyclobutene-1,2-dione, 3 ,S-dioxo-1,2,4-oxadiazolidinyl, 3-hydroxyisoxazolyl and 3-hydroxy-1 -methylpyrazolyl; hydroxy, alkyl substituted by carboxy, heteroaryl, or R2 is -OR 4 in which R4 is ailcyl, -OR 4 in which R4 is alkyl or cycloalkylalkyl substituted by one or more hydroxy groups, -OR4 in which R4 is alkyl substituted by one or more aloxy groups, -OR 4 in which R4 is alkyl or cycloalkyl substituted by one or more carboxy groups, -OR4 in which 1R4 is cycloalkyl substituted by -C(=O)-NY 1 Y 2 or R2 is in which R is alkyl, or R2 is NY 1 Y 2 or -N(R 6 7 6. A compound according to claim 1 wherein R2 is -OCI-3 or -CONC(CH 3 7. A compound according to claim 1 wherein R is -OCHj. 8. A compound according to claim I wherein R3 is hydrogen, cyano, optionally substituted aryl, optionally substituted heteroaryl, alkyl, alkyl substituted by one or more halogen atoms, alkyl substituted by -C(=O)-NYlY 2 alkyl substituted by -OR7, or R3 is -ZR 4 -C(=O)-NYlY 2 or -NY Y 2 COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10 10-Dec-2008 17:06 Watermark +61298887600 14/38 00 57 0 O 9. A compound according to claim 1 wherein R3 is hydrogen, cyano, pyridyl, trifluoromethyl, -CI-12-CI-I2-C(=O)NI-IC-T, -OCF2H, -C(=0)-NH-C(CH 32 -CH 2 H or A compound according to claim 1 wherein R 3 is -OCH3. en
11. A compound according to claim 1 wherein R 2 is attached at the 5-position of the indole ring, c
12. A compound according to claim I wherein the group is attached to the 3-position of the indole ring. H
13. A compound according to claim 1, which is selected from the group consisting of: Me cr 3 C3HOH M m e olu e o ma Mo O 144 COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10 10-Dec-2008 17:07 Watermark +61298887600 15/38 00 58 OH 0 0 MN mo C)N aH H Hn 3F~. 0N 2x MN N OO lq,, Oe /e Ose >1 K- e H~I\L H HI I! It H H IjI na N COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10 10-Dec-2008 17:07 atermark +61298887600 16/38 0059 O o~ Mao Cci o Ma A N N cysm o a o c M oM o H H o H H CN3 MeMe NNH 1N H H HH N-oxides, pharmaceutically acceptable salts of the above listed compounds; and N-oxides of said salts. COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10 10-Dec-2008 17:08 Watermark +61298887600 17/38 00 O O 14. A compound according to claim 1 which is M Mao or an N-oxide, pharmaceutically acceptable salt of such compound; or an N-oxide of such salta A compound substantially as mmereinbefor described with reference to the title compound of any one ofring to said mples a pharmaceuticallyto 12. 0 one16. A phclarmaeutical composihaaceution comprising a pharmaeutically e tive amount of a compound according to any one of claim 1 to 15, together winfla one atory disease phais saceutcally acceptable earthoders or dxcipicnts. asthm A method of treating a patient suffering fom, or subject to conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of one or more protein kinases selected from Syk, FAK, KDR and Aurora2, the method comprising administering to said patient a pharmaceutically effective amount of a compound according to any one of claims I to or a pharmaceutically effective amount of a composition according to claim 16.
18. A method of treating inflammatory disease in a patient, the method comprising administering to said patient a pharmaceutically effective amount of a compound according to any one of claims I to 15, or a phannaceutically effective amount of a composition according to claim 16.
19. A method according to claim 18 wherein the inflammatory disease is selected from asthma, inflammatory dermatosis, allergic rhinitis, allergic conjunctivitis and joint inflammation.
20. A method according to claim 18 wherein the inflammatory disease is selected from asthma, psoriasis, dermatitis hcpetiformis, eczema, necrotizing vasculitis, cutaneous vasculitis, bullous disease, allergic rhinitis, allergic conjunctivitis, arthritis, rheumatoid arthritis, rabella arthritis, psoriatic aithritis and osteoarthritis.
21. A method of treating cancer in a patient, the method comprising administering to said patient a pharmaceutically effective amount of a compound according to any one of claims 1 to or a pharmaceutically effective amount of a composition according to claim 16. COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10 lO-Dec-2008 17:09 Watermark +61298887600 18/38 00 61 0 O
22. A method according to claim 21 wherein the cancer- being treated is selected from colorectal, prostate, breast, thyroid, skin, colon and lung cancer. C) S23. A method of treating Chronic Obstructive Pulmhnonary Disease in a patient, the method Scomprising administering to said patient a pharmaceutically effective amount of a compound according to any one of claims 1 to 15, or a phannrmaceutically effective amount of a composition l~ according to claim 16.
24. Use of a compound according to any one of claims 1 to 15 in the manufacture of a f medicament for treating a patient suffering from, or subject to, conditions which can be Sameliorated by the administration of an inhibitor of the catalytic activity of one or more protein S 10 kinases selected from Syk, FAK, KDR and Aurora2. Use of a compound according to any one of claims J to 15 in the manufacture of a medicament for treating inflammatory disease in a patient.
26. Use of a compound according to any one of claims I to 15 in the manufacture of a medicament for treating cancer in a patient
27. Use of a compound according to any one of claims I to 15 in the manufacture of a medicament for treating Chronic Obstructive Pulmonary Disease in a patient AVENTIS PHARMACEUTICALS INC WATERMARK PATIENT TRADE MARK ATTORNEYS P23484AUU00 COMS ID No: ARCS-216599 Received by IP Australia: Time 17:29 Date 2008-12-10
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115393.1A GB0115393D0 (en) | 2001-06-23 | 2001-06-23 | Chemical compounds |
GB0115393.1 | 2001-06-23 | ||
US30167801P | 2001-06-28 | 2001-06-28 | |
US60/301,678 | 2001-06-28 | ||
PCT/GB2002/002835 WO2003000695A1 (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as protein kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2002314325A1 AU2002314325A1 (en) | 2003-06-19 |
AU2002314325B2 AU2002314325B2 (en) | 2009-01-08 |
AU2002314325B8 true AU2002314325B8 (en) | 2009-01-29 |
Family
ID=9917225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002314325A Ceased AU2002314325B8 (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as protein kinase inhibitors |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1404676A1 (en) |
JP (1) | JP4344607B2 (en) |
CN (1) | CN1294135C (en) |
AU (1) | AU2002314325B8 (en) |
BR (1) | BR0210652A (en) |
CA (1) | CA2451932C (en) |
CZ (1) | CZ20033443A3 (en) |
EA (1) | EA007415B1 (en) |
EC (1) | ECSP034922A (en) |
EE (1) | EE05432B1 (en) |
GB (1) | GB0115393D0 (en) |
HU (1) | HUP0400300A3 (en) |
ME (1) | MEP19308A (en) |
NZ (1) | NZ529766A (en) |
OA (1) | OA12632A (en) |
PL (1) | PL374096A1 (en) |
RS (1) | RS51698B (en) |
SK (1) | SK15882003A3 (en) |
TN (1) | TNSN03144A1 (en) |
TR (1) | TR200302242T2 (en) |
UA (1) | UA76760C2 (en) |
WO (1) | WO2003000695A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
EP1687309A1 (en) | 2003-11-17 | 2006-08-09 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
BRPI0416909A (en) * | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | atherosclerosis treatment method |
US20050250829A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Kinase inhibitors |
FR2876103B1 (en) * | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
FR2878849B1 (en) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
JP2010505962A (en) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | Kinase inhibitor |
EP3495369B1 (en) | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
NZ586642A (en) | 2008-01-11 | 2012-04-27 | Natco Pharma Ltd | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
PE20140407A1 (en) | 2008-06-10 | 2014-04-25 | Abbott Lab | NEW TRICYCLIC COMPOUNDS |
MX2011012262A (en) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors. |
EA025520B1 (en) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
TW201802091A (en) * | 2009-12-01 | 2018-01-16 | 艾伯維有限公司 | Novel tricyclic compounds |
SI3354652T1 (en) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
BR112013012502A2 (en) | 2010-11-19 | 2019-03-06 | Incyte Corporation | substituted cyclobutyl pyrrolopyridine and derivative pyrrolopyrimidine derivatives as jak inhibitors |
CN102093364B (en) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor |
CN103476776B (en) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
JP6182593B2 (en) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | Substituted heterobicyclic compounds, compositions and medicaments and uses thereof |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
DK2877467T3 (en) | 2012-07-26 | 2017-02-13 | Glaxo Group Ltd | 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS |
JP6318156B2 (en) * | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドPlexxikon Inc. | Compounds and methods for modulating kinases and indicators thereof |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
EA030705B1 (en) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Processes and intermediates for making a jak inhibitor |
AU2014244263A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | CDK9 kinase inhibitors |
BR112015021549A2 (en) | 2013-03-13 | 2017-07-18 | Abbvie Inc | pyridine kinase cdk9 inhibitors |
WO2014151444A1 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
AU2014231567A1 (en) | 2013-03-14 | 2015-10-01 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors |
JP2016512560A (en) * | 2013-03-14 | 2016-04-28 | アッヴィ・インコーポレイテッド | Pyrrolopyrimidine CDK9 kinase inhibitor |
ES2792549T3 (en) | 2013-08-07 | 2020-11-11 | Incyte Corp | Sustained-release dosage forms for a JAK1 inhibitor |
CN104804001B9 (en) * | 2014-01-24 | 2022-02-08 | 江苏柯菲平医药股份有限公司 | 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
SG10201913986YA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
WO2018165581A1 (en) | 2017-03-09 | 2018-09-13 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
PL3746429T3 (en) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
EP3860998B1 (en) | 2018-10-05 | 2023-12-27 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065909A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO1999065908A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1441497A (en) * | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
BR9713552A (en) * | 1996-11-27 | 2000-01-25 | Pfizer | Condensed bicyclic pyrimidine derivatives |
CZ2001959A3 (en) * | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidines functioning as kinase inhibitors |
-
2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
-
2002
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/en not_active Expired - Fee Related
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/en unknown
- 2002-06-21 PL PL02374096A patent/PL374096A1/en not_active Application Discontinuation
- 2002-06-21 EA EA200400073A patent/EA007415B1/en not_active IP Right Cessation
- 2002-06-21 UA UA2004010502A patent/UA76760C2/en unknown
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/en not_active Application Discontinuation
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 EP EP02740895A patent/EP1404676A1/en not_active Withdrawn
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/en not_active Application Discontinuation
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/en active Application Filing
- 2002-06-21 CA CA002451932A patent/CA2451932C/en not_active Expired - Fee Related
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/en unknown
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/en unknown
- 2002-06-21 CN CNB028119320A patent/CN1294135C/en not_active Expired - Fee Related
- 2002-06-21 EE EEP200400003A patent/EE05432B1/en not_active IP Right Cessation
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/en unknown
-
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065909A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO1999065908A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
Also Published As
Publication number | Publication date |
---|---|
CN1518552A (en) | 2004-08-04 |
ECSP034922A (en) | 2004-04-28 |
JP2005508300A (en) | 2005-03-31 |
WO2003000695A1 (en) | 2003-01-03 |
RS99203A (en) | 2006-12-15 |
TR200302242T2 (en) | 2004-12-21 |
EA007415B1 (en) | 2006-10-27 |
NZ529766A (en) | 2008-11-28 |
MEP19308A (en) | 2010-06-10 |
JP4344607B2 (en) | 2009-10-14 |
CN1294135C (en) | 2007-01-10 |
SK15882003A3 (en) | 2004-07-07 |
HUP0400300A3 (en) | 2010-12-28 |
HUP0400300A2 (en) | 2007-08-28 |
AU2002314325B2 (en) | 2009-01-08 |
RS51698B (en) | 2011-10-31 |
EE200400003A (en) | 2004-02-16 |
EP1404676A1 (en) | 2004-04-07 |
CA2451932A1 (en) | 2003-01-03 |
CA2451932C (en) | 2009-12-29 |
BR0210652A (en) | 2004-08-10 |
EA200400073A1 (en) | 2004-08-26 |
PL374096A1 (en) | 2005-09-19 |
GB0115393D0 (en) | 2001-08-15 |
UA76760C2 (en) | 2006-09-15 |
TNSN03144A1 (en) | 2005-12-23 |
EE05432B1 (en) | 2011-06-15 |
CZ20033443A3 (en) | 2004-03-17 |
WO2003000695A8 (en) | 2004-03-11 |
OA12632A (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002314325B8 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
AU2002314325A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
US7259154B2 (en) | Pyrrolopyrimidines | |
CA2395593C (en) | Azaindoles | |
CN116194456A (en) | Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof | |
KR20140095477A (en) | Macrocyclic lrrk2 kinase inhibitors | |
JP2010520294A (en) | Metalloprotease inhibitors containing heterocyclic moieties | |
WO2010070237A1 (en) | Derivatives of 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine and 6-cycloamino-2-furanyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof | |
ES2382759T3 (en) | Azaindoles | |
WO2021239727A1 (en) | 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer | |
JP2024503273A (en) | Heteroaryl derivative compounds and their uses | |
TW202406542A (en) | A kif18a inhibitor and use thereof | |
ZA200309315B (en) | Pyrrolopyrimidines as protein kinase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH | Corrigenda |
Free format text: IN VOL 23, NO 1, PAGE(S) 6139 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME AVENTIS PHARMACEUTICALS INC, APPLICATION NO. 2002314325, UNDER INID(72), CORRECT THE CO-INVENTOR NAME TO AMENDOLA, SHELLEY |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |